Esperion Therapeutics (NASDAQ:ESPR) Price Target Raised to $5.00

Esperion Therapeutics (NASDAQ:ESPR) had its price objective increased by Needham & Company LLC from $4.00 to $5.00 in a research report report published on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citigroup reaffirmed a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a report on Wednesday, November 12th. Finally, Piper Sandler started coverage on shares of Esperion Therapeutics in a report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Esperion Therapeutics Price Performance

ESPR stock opened at $2.77 on Tuesday. The firm has a 50 day simple moving average of $3.41 and a two-hundred day simple moving average of $3.11. The stock has a market cap of $662.20 million, a PE ratio of -5.54, a P/E/G ratio of 0.60 and a beta of 1.11. Esperion Therapeutics has a one year low of $0.69 and a one year high of $4.18.

Insider Buying and Selling at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 15,543 shares of company stock worth $55,709 in the last ninety days. Corporate insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ESPR. DHJJ Financial Advisors Ltd. grew its position in shares of Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 6,380 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter valued at $25,000. Vanguard Personalized Indexing Management LLC purchased a new position in Esperion Therapeutics during the 3rd quarter valued at $29,000. R Squared Ltd bought a new position in Esperion Therapeutics in the 3rd quarter worth $33,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Esperion Therapeutics in the 4th quarter worth about $35,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.